Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination

Figures & data

Figure 1 The relation of insulin resistance, β-cell dysfunction, obesity, and their associated complications.

Figure 2 Chemical structures of glimepiride and rosiglitazone.

Table 1 Overview on the clinical studies applying a combination of rosiglitazone and a SU drug in comparison with uptitration of the SU in patients failing on low dose SU therapy

Combination Rosiglitazone+	Size and duration	Results	References
Rosiglitazone addition
Glipizide	n = 340 26 weeks	Better HbA1c and FPG with the combination vs uptitration of glipizide alone. More hypoglycemic events and mild edema with the combination. Patients with the combination gained significantly more weight than with SU alone.	Kerenyi et al 2004
Gliclazide	n = 471 26 weeks	Better HbA1c and FPG with the combination vs uptitration of gliclazide alone. More hypoglycemic events and oedema with the combination. Patients with the combination gained significantly more weight than with SU alone.	Baksi et al 2004
Glibenclamide	n = 227 2 years	Better HbA1c and FPG with the combination vs uptitration of glibenclamide alone. Comparable incidence of hypoglycaemic events. More mild oedema with the combination. Patients with the combination gained significantly more weight than with SU alone.	Rosenstock et al 2005Herman et al 2005
Glimepiride	n = 391 30 weeks	Better HbA1c and FPG with the combination vs uptitration of glimepiride alone. More hypoglycaemic events and mild oedema with the combination. Patients with the combination gained significantly more weight than with SU alone.	Rosenstock et al 2005
Glimepiride	n = 174 26 weeks	Better HbA1c and FPG with the combination (with uptitration of rosiglitazone) vs glimepiride alone. Improvement of inflammatory risk markers, insulin resistance and β-cell function in the rosiglitazone arms only. Comparable incidence of hypoglycemic events. More mild edema with the combination. Patients with the 8 mg combination gained significantly more weight than with SU alone.	Hamann et al 2003Pfützner et al 2006a
Glimepiride addition
Glimepiride	n = 40 26 weeks	Better HbA1c and FPG with the combination in patients failing on rosiglitazone monotherapy. No increase in hypoglycemic episodes or other adverse events.	McCluskey et al 2004

Abbreviations: FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; SU, sulfonylurea.

KerenyiZSamerHJamesRCombination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients wit type 2 diabetes mellitusDiabetes Res Clin Pract2004632132314757293

 PubMed Web of Science ®Google Scholar

BaksiAJamesREZhouBComparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylureaActa Diabetol20044163915224207

 PubMed Web of Science ®Google Scholar

RosenstockJGoldsteinBJVinikAIEffect of early addition of rosiglitazone to sulphonylurea therapy in older patients with type 2 diabetes (>60 years): the Rosiglitazone Early vs SULfonylurea Titration (RESULT) studyDiabetes Obes Metab20058495716367882

 PubMed Web of Science ®Google Scholar

HermanWHDiraniRGHorblyukRReduction in use of health-care services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) studyAm J Manag Care200511273815839187

 PubMed Web of Science ®Google Scholar

HamannAMatthaeiSMauersbergerHEfficacy and Safety of Rosiglitazone in Combination with GlimepirideDiabetes Metab200329Suppl 22288

 Google Scholar

PfütznerASchöndorfTSeidelDImpact of rosiglitazone on β-cell function, insulin resistance and adiponektin concentrations— Results from a double blind oral combination study with glimepirideMetabolism2006a55205

 PubMed Web of Science ®Google Scholar

McCluskeyDTougerMSMelisRResults of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapyClin Ther20042617839015639690

 PubMed Web of Science ®Google Scholar